PUMA BIOTECHNOLOGY, INC. Repayments of Debt
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Repayments of Debt of $22.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. repayments of debt for the quarter ending 2026-06-30 was $11.12M, a 0.09% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. repayments of debt for the quarter ending 2026-03-31 was $11.11M, a 0.00% change year-over-year.
- PUMA BIOTECHNOLOGY, INC. repayments of debt for the quarter ending 2025-12-31 was $11.11M, a 0.00% change year-over-year.
- PUMA BIOTECHNOLOGY, INC. repayments of debt for the quarter ending 2025-09-30 was $11.11M, a 0.00% change year-over-year.
- PUMA BIOTECHNOLOGY, INC. repayments of debt for fiscal 2025 was $44.44M, a 33.33% increase from fiscal 2024.
- PUMA BIOTECHNOLOGY, INC. repayments of debt for fiscal 2024 was $33.33M.
- PUMA BIOTECHNOLOGY, INC. repayments of debt for fiscal 2023 was $0.00.
- PUMA BIOTECHNOLOGY, INC. repayments of debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Repayments of Debt 3 month | Repayments of Debt 6 month | Repayments of Debt 9 month | Repayments of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $22.23M 10-Q · filed 2026-08-06 | $33.34M derived: sum of 3 quarters · filed 2026-08-06 | $44.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $11.11M 10-Q · filed 2026-05-07 | $22.22M derived: sum of 2 quarters · filed 2026-05-07 | $33.33M derived: sum of 3 quarters · filed 2026-05-07 | $44.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $11.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $22.22M derived: sum of 2 quarters · filed 2026-02-26 | $33.33M derived: sum of 3 quarters · filed 2026-08-06 | $44.44M 10-K · filed 2026-02-26 |
| 2025-09-30 | $11.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $22.22M derived: sum of 2 quarters · filed 2026-08-06 | $33.33M 10-Q · filed 2025-11-06 | $44.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $11.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $22.22M 10-Q · filed 2026-08-06 | $33.33M derived: sum of 3 quarters · filed 2026-08-06 | $44.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $11.11M 10-Q · filed 2026-05-07 | $22.22M derived: sum of 2 quarters · filed 2026-05-07 | $33.33M derived: sum of 3 quarters · filed 2026-05-07 | $44.44M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $11.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $22.22M derived: sum of 2 quarters · filed 2026-02-26 | $33.33M derived: sum of 3 quarters · filed 2026-02-26 | $33.33M 10-K · filed 2026-02-26 |
| 2024-09-30 | $11.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $22.22M derived: sum of 2 quarters · filed 2025-11-06 | $22.22M 10-Q · filed 2025-11-06 | $22.22M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $11.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $11.11M 10-Q · filed 2025-08-07 | $11.11M derived: sum of 3 quarters · filed 2026-02-26 | $11.11M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $100.00M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $100.00M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $0.00 derived: sum of 2 quarters · filed 2023-03-02 | $8.44M 10-K · filed 2023-03-02 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $8.44M 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $8.44M 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $0.00 derived: sum of 2 quarters · filed 2022-03-03 | $80.00M 10-K · filed 2022-03-03 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $80.00M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $80.00M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |